fms-related tyrosine kinase 3 ligand

Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3 STK1), colony-stimulating factor 1 receptor (CSF1R FMS), stem cell factor receptor (SCFR KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Adezkibart 是一种靶向人源 FMS 样酪氨酸激酶 3 配体 (FLT3LG) 的人源单克隆抗体类免疫抑制剂。在中国仓鼠卵巢细胞系 CHO-K1 中发现，它通过与 FLT3LG 结合来阻断信号通路，从而抑制免疫反应，起到免疫抑制的作用。Adezkibart 可能在免疫相关疾病的研究中发挥作用。